Bod Australia Limited announced that it has completed a proof of concept study into the safety and efficacy of a cannabigerol (CBG) dominant cannabis extract which has shown very promising results. The study will form the basis for the launch of a new medicinal cannabis product that will be sold under Bod's existing medicinal cannabis brand as MediCabilisTM CBG 50, expected to launch in June 2022. CBG is a non-intoxicating cannabinoid compound, found in the cannabis plant.

It holds strong therapeutic potential across a range of applications. Preliminary research has indicated that CBG has unique pharmacological actions and has the potential to address alternative therapeutic areas to THC and CBD. The extract has been shown to be beneficial in the treatment of fibromyalgia, inflammatory bowel disease and irritable bowel syndrome (IBS) amongst others.

Treatment of these conditions commonly includes a mix medication, surgery and self-care strategies, with no single treatment procedure working on all symptomsi. Bod's proof of concept study was conducted over a three month period to assess the safety and efficacy of MediCabilisTM CBG 50 in patients suffering from symptoms associated with fibromyalgia, inflammatory bowel disease and anxiety. During the trial, participants were administered 50mg/ml of the product orally, twice daily and asked to rate the improvement in symptoms on a scale of one to ten, with one being nothing to ten being the best improvement.

A comprehensive review of the data highlighted that 74% of trial participants reported a noticeable improvement in their conditions within two to four weeks of using MediCabilisTM CBG 50 twice a day. When participants were asked to rate the improvement on a scale of one to ten, 64% reported a rating above six. The detailed trial data will be shared with doctors and approved prescribers in both Australia and the UK to assist in the ongoing educational initiatives undertaken by the Company and to support the launch of MediCabilisTM CBG 50.

The Company expects to launch MediCabilisTM CBG 50 in June 2022 via prescription channels. This will complement and expand Bod's existing medicinal cannabis product range, which is currently being used to alleviate a range of conditions including chronic pain, anxiety and insomnia amongst others. Bod will also become the first company to launch a pharmaceutical grade CBG product in the Australian and UK prescription market, providing another channel to grow medicinal cannabis sales.